Phase 1 trial will assess the safety, pharmacokinetic and pharmacodynamic profile of BCX4161, a novel selective inhibitor of plasma kallikrein, in healthy volunteers.
The study that is being conducted at Quotient Clinical in the UK, leverages an integrated Translational Pharmaceutics platform.
BioCryst president and chief executive officer Jon Stonehouse said the daily, oral administration of a safe and efficacious prophylactic drug would revolutionise treatment for HAE patients.
"BCX4161 has the potential to be the first oral treatment developed specifically for the prevention of HAE attacks," Stonehouse added.
Measuring safety, characterising plasma drug levels, and estimating the acheived level of kallikrein inhibition subsequent to oral dosing of BCX4161 incude the study’s goals.
The results from the study are anticipated in 2013.
Upon reaching the objectives, a planned Phase 2 programme in HAE patients will commence.